SymBiosis reports 4.43M Rani shares (4.4%)

Rani Therapeutics Holdings, Inc. filing amends a previously reported Schedule 13G to show SymBiosis Capital Partners, LLC beneficially owns 4,433,620 shares of Class A Common Stock, representing 4.4% of the class.

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. filing amends a previously reported Schedule 13G to show SymBiosis Capital Partners, LLC beneficially owns 4,433,620 shares of Class A Common Stock, representing 4.4% of the class. The filing lists sole voting and dispositive power over 4,433,620 shares. The amendment is signed by the reporting firm's Managing Partner on 05/15/2026.

Insights

Institutional Holdings Analyst

Large holder reports a sub-5% passive stake and sole control of votes and dispositions.

SymBiosis Capital Partners, LLC is disclosed as beneficial owner of 4,433,620 shares, equal to 4.4% of Class A Common Stock. The filing states sole voting and dispositive power over the same share count, indicating direct control of the reported stake.

Because the stake is under 5% and labeled under the filing's ownership category, this is a routine institutional disclosure; subsequent filings would show changes in percentage or ownership.

Compliance & Filings Specialist

The amendment updates a Schedule 13G ownership disclosure with an executed signature date.

The document is an Amendment No. 1 to a Schedule 13G/A naming the reporting person and providing CUSIP 0753018100. It includes the reporting firm's address and Delaware organization status, consistent with standard beneficial ownership filings.

For confirmations, check future amendments or Form 13D if the holder's intent or percentage crosses reporting thresholds.

Key Figures

Beneficial ownership: 4,433,620 shares Percent of class: 4.4% Sole voting power: 4,433,620 shares +3 more

6 metrics

Beneficial ownership 4,433,620 shares Amount beneficially owned (Class A Common Stock)

Percent of class 4.4% Percent of Class A Common Stock

Sole voting power 4,433,620 shares Sole power to vote or direct the vote

Sole dispositive power 4,433,620 shares Sole power to dispose or direct disposition

CUSIP 0753018100 Class A Common Stock identifier

Signature date 05/15/2026 Date the amendment was signed

Key Terms

Schedule 13G/A, Beneficially owned, Sole Dispositive Power, CUSIP

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 to Schedule 13G/A appears at top of document"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4(a) Amount beneficially owned: 4,433,620"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power regulatory

"Item 4(c)(iii) Sole power to dispose: 4,433,620"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

CUSIP technical

"CUSIP No.: 0753018100 listed under Item 2(d)/(e)"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does SymBiosis Capital report in RANI?

SymBiosis reports beneficial ownership of 4,433,620 shares, equal to 4.4% of Class A Common Stock. The filing shows the firm has sole voting and dispositive power over the same 4,433,620 shares, per the amendment signed 05/15/2026.

Does SymBiosis control voting for those RANI shares?

Yes. The disclosure states SymBiosis has sole power to vote and sole power to dispose of 4,433,620 shares. Those powers are explicitly listed in the ownership table of the Schedule 13G amendment.

Is SymBiosis's position in RANI an active greater-than-5% stake?

No. The filing classifies the position as 4.4%, which is under the 5% threshold referenced in the form. The document also labels the filing under the 'Ownership of 5 Percent or Less of a Class' section.

When was the Schedule 13G/A amendment signed?

The amendment is signed by the Managing Partner of SymBiosis on 05/15/2026. The cover shows CUSIP 0753018100 and the filing is titled Amendment No. 1 for this Schedule 13G/A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 11:31 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Rani Therapeutics Holdings, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

0753018100

(CUSIP Number)

03/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 0753018100

1

Names of Reporting Persons

SymBiosis Capital Partners, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,433,620.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,433,620.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,433,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rani Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 2051 RINGWOOD AVENUE, 2051 RINGWOOD AVENUE, SAN JOSE, CALIFORNIA, 95131.
Item 2.
(a)	Name of person filing: SymBiosis Capital Partners, LLC
(b)	Address or principal business office or, if none, residence: 609 SW 8TH STREET, SUITE 510 BENTONVILLE, AR 72712
(c)	Citizenship: Delaware
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 0753018100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,433,620
(b)	Percent of class: 4.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,433,620
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,433,620
	(iv) Shared power to dispose or to direct the disposition of: 4,433,620
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SymBiosis Capital Partners, LLC

Signature:	/s/ Chidozie Ugwumba
Name/Title:	Managing Partner
Date:	05/15/2026